Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of Bruton’s tyrosine kinase in B cells and malignancies
Simar Pal Singh, Floris Dammeijer, Rudi W. Hendriks
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 606

Showing 1-25 of 606 citing articles:

Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
Pharmacological Research (2019) Vol. 144, pp. 19-50
Closed Access | Times Cited: 489
Advances in covalent drug discovery
Lydia Boike, Nathaniel J. Henning, Daniel K. Nomura
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 12, pp. 881-898
Open Access | Times Cited: 481
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Ivan Jelčić, Faiez Al Nimer, Jian Wang, et al.
Cell (2018) Vol. 175, Iss. 1, pp. 85-100.e23
Open Access | Times Cited: 402
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Constantine S. Tam, Stephen Opat, Shirley D’Sa, et al.
Blood (2020) Vol. 136, Iss. 18, pp. 2038-2050
Open Access | Times Cited: 369
Molecular targeted therapy for anticancer treatment
Hye‐Young Min, Ho‐Young Lee
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1670-1694
Open Access | Times Cited: 258
Advances in covalent kinase inhibitors
Ayah Abdeldayem, Yasir S. Raouf, Stefan N. Constantinescu, et al.
Chemical Society Reviews (2020) Vol. 49, Iss. 9, pp. 2617-2687
Closed Access | Times Cited: 256
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
H. Yesid Estupiñán, Anna Berglöf, Rula Zain, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 187
Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
George Crișan, Nastasia Sanda Moldovean-Cioroianu, Diana-Gabriela Timaru, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5023-5023
Open Access | Times Cited: 184
B Cells in Rheumatoid Arthritis：Pathogenic Mechanisms and Treatment Prospects
Fengping Wu, Jinfang Gao, Jie Kang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 171
Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
Ronen Gabizon, Amit Shraga, Paul Gehrtz, et al.
Journal of the American Chemical Society (2020) Vol. 142, Iss. 27, pp. 11734-11742
Open Access | Times Cited: 165
FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications
Julhash U. Kazi, Lars Rönnstrand
Physiological Reviews (2019) Vol. 99, Iss. 3, pp. 1433-1466
Closed Access | Times Cited: 154
The B-Side of Cancer Immunity: The Underrated Tune
Anne Largeot, Giulia Pagano, Susanne Gonder, et al.
Cells (2019) Vol. 8, Iss. 5, pp. 449-449
Open Access | Times Cited: 151
Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy
Luming Yang, Zhaole Chu, Meng Liu, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 151
Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, et al.
Neuro-Oncology (2020) Vol. 23, Iss. 1, pp. 122-133
Open Access | Times Cited: 139
Phosphorylation-Inducing Chimeric Small Molecules
Sachini U. Siriwardena, Dhanushka N. P. Munkanatta Godage, Veronika M. Shoba, et al.
Journal of the American Chemical Society (2020) Vol. 142, Iss. 33, pp. 14052-14057
Closed Access | Times Cited: 139
Orelabrutinib: First Approval
Sohita Dhillon
Drugs (2021) Vol. 81, Iss. 4, pp. 503-507
Closed Access | Times Cited: 108
Bruton tyrosine kinase inhibitors for multiple sclerosis
Julia Krämer, Amit Bar‐Or, Timothy J. Turner, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 5, pp. 289-304
Open Access | Times Cited: 100
Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells
Κωνσταντίνος Μελισσαρόπουλος, George Iliopoulos, Lazaros I. Sakkas, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 88
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
Aqu Alu, Hong Lei, Xuejiao Han, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 87
Protein kinases: drug targets for immunological disorders
Leslie Castelo‐Soccio, Hanna Kim, Massimo Gadina, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 12, pp. 787-806
Open Access | Times Cited: 57
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 51
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Pier Luigi Zinzani, Jiřı́ Mayer, Christopher R. Flowers, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 33, pp. 5107-5117
Open Access | Times Cited: 49
Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2400-2400
Open Access | Times Cited: 47
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
Daniel Robbins, Mark Noviski, Ying Siow Tan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2321-2336
Open Access | Times Cited: 42
NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders
Rajath Ramachandran, Abdul Manan, Jei Kim, et al.
Experimental & Molecular Medicine (2024) Vol. 56, Iss. 7, pp. 1488-1500
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top